Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565937 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution
A NA study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 295
- Enrollment target
NCT05565937: Completed NA study, sponsored by Bausch & Lomb Incorporated.
NCT05565937 is a NA study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 295 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05565937, a NA study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 295 participants
- Enrollment target
Study Summary
Approximately 340 participants (680 eyes) will be enrolled in this three-month, two-arm, 1:1 randomized, parallel-group, bilateral, double-masked study at approximately 22 investigative sites in the United States. Participants will be required to wear dispensed study lenses on a daily wear basis for three months with scheduled in-office replacement of study lenses at the 1-Month and 2-Month Follow-Up Visits.
Primary Outcome
Overall comfort will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response
Interventions
- DEVICE BL-3100-NBR03 multi-purpose solution
- DEVICE renu® Advanced Formula multi-purpose solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2024-02-28 |
| Phase | NA |
What the finished NCT05565937 record still lists
NCT05565937 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which BL-3100-NBR03 multi-purpose solution is the first listed.
NCT05565937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05565937 about?
NCT05565937 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution". Approximately 340 participants (680 eyes) will be enrolled in this three-month, two-arm, 1:1 randomized, parallel-group, bilateral, double-masked study at approximately 22 investigative sites in the United States. Participants will be required to wear dispensed study lenses on a daily wear basis for...
What is the current status of trial NCT05565937?
This trial is currently completed. It is a NA study. The enrollment target is 295 participants. The study started on 2023-04-12. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05565937?
The interventions under investigation include: BL-3100-NBR03 multi-purpose solution (DEVICE), renu® Advanced Formula multi-purpose solution (DEVICE).
Who is sponsoring clinical trial NCT05565937?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05565937's enrollment target sits among peer trials
295 373rd of 2000 higher than 1,628 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI